


**Figure S1** Data of patients in the CRT and RT groups before and after PSM. (A,B) Data of patients in the CRT group before and after PSM. (C,D) Data of patients in the RT group before and after PSM. CRT, chemoradiotherapy; RT, radiotherapy; PSM, propensity score matching.



**Figure S2** Data of patients in the Neo + S and CRT groups before and after PSM. (A,B) Data of patients in the Neo + S group before and after PSM. (C,D) Data of patients in the CRT group before and after PSM. Neo + S, neoadjuvant therapy combined with surgery; CRT, chemoradiotherapy; PSM, propensity score matching.

**Table S1** Baseline characteristics of esophageal cancer patients with supraclavicular lymph node metastasis

Variables	Total	Percentage (%)
Age		
<65	119	51.5
≥65	112	48.5
Sex		
Male	153	66.2
Female	78	33.8
BMI		
<22.34	109	47.2
≥22.34	122	52.8
Supraclavicular lymph node metastasis		
Left	85	36.8
Right	72	31.2
Bilateral	74	32.0
Location		
Upper	64	27.7
Middle	138	59.7
Lower	29	12.6
TNM stage		
IIB–IIIA	56	24.2
IIIB	145	62.8
IVA	30	13.0
Surgery		
Yes	57	24.7
No	174	75.3
Surgery item		
Surgery only	16	28.1
Neoadjuvant chemotherapy	40	70.2
Neoadjuvant RT	1	1.7
Lymphadenectomy <sup>†</sup>		
Left	12	29.3
Right	14	34.1
Bilateral	15	36.6
Radiation		
Yes	169	73.2
No	62	26.8
Chemotherapy		
Yes	190	82.3
No	41	17.7
Cause of death		
Cancer-specific death	95	41.1
Other-cause death	13	5.6
Alive	123	53.3

<sup>†</sup>, patients who did not receive neoadjuvant therapy were excluded. BMI, body mass index; TNM, tumor node metastasis classification; RT, radiotherapy.

**Table S2** Metastatic sites of tumors with different primary sites

Site of metastasis	Primary site of tumor					
	Upper		Middle		Lower	
	N	N%	N	N%	N	N%
Recurrence <i>in situ</i>	0	0.00	0	0.00	5	50.00
Supraclavicular lymph nodes	12	41.38	23	42.59	2	20.00
Mediastinal lymph nodes	9	31.03	25	46.30	4	40.00
Abdominal lymph nodes	4	13.79	19	35.19	7	70.00
Axillary lymph nodes	1	3.45	5	9.26	0	0.00
Subcarinal lymph nodes	1	3.45	2	3.70	0	0.00
Liver metastasis	2	6.90	6	11.11	0	0.00
Bone metastasis	4	13.79	5	9.26	0	0.00
Lung metastasis	11	37.93	7	12.96	0	0.00
Splenic metastasis	0	0.00	3	5.56	0	0.00
Brain metastasis	0	0.00	2	3.70	0	0.00
Pleural metastasis	0	0.00	2	3.70	0	0.00

N% refers to the percentage of the number of metastasis to a specific site out of the total number of metastatic cases. For example, 19 patients were found to have tumor metastasis or recurrence, of which 12 patients had supraclavicular lymph node metastasis,  $n\% = 12/19 = 41.38\%$  for supraclavicular lymph node metastasis.